Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link. All three major indices are trading down today with the Dow Jones Industrial Average ( ^DJI) trading down 128 points (-0.8%) at 16,374 as of Friday, April 25, 2014, 1:00 PM ET. The NYSE advances/declines ratio sits at 926 issues advancing vs. 2,054 declining with 148 unchanged. The Health Services industry currently sits down 0.9% versus the S&P 500, which is down 0.7%. On the negative front, top decliners within the industry include PerkinElmer ( PKI), down 3.4%, Intuitive Surgical ( ISRG), down 1.6%, Aetna ( AET), down 1.6%, Thermo Fisher Scientific ( TMO), down 1.1% and UnitedHealth Group ( UNH), down 1.1%. TheStreet would like to highlight 3 stocks pushing the industry lower today: 3. Covidien ( COV) is one of the companies pushing the Health Services industry lower today. As of noon trading, Covidien is down $1.82 (-2.6%) to $69.14 on heavy volume. Thus far, 3.8 million shares of Covidien exchanged hands as compared to its average daily volume of 2.1 million shares. The stock has ranged in price between $67.68-$69.50 after having opened the day at $69.39 as compared to the previous trading day's close of $70.96. Covidien plc develops, manufactures, and sells healthcare products for use in clinical and home settings worldwide. Covidien has a market cap of $31.8 billion and is part of the health care sector. Shares are up 4.2% year-to-date as of the close of trading on Thursday. Currently there are 15 analysts that rate Covidien a buy, no analysts rate it a sell, and 2 rate it a hold. TheStreet Ratings rates Covidien as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, notable return on equity, reasonable valuation levels, good cash flow from operations and largely solid financial position with reasonable debt levels by most measures. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Covidien Ratings Report now. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12 months. Learn more.
Ikaria, which focuses on therapies for critically ill infants, is privately owned by a group led by Madison Dearborn Partners. Buyer Mallinckrodt specializes in diagnostic radiology and pain management.